Compare EFR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFR | CAPR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.8M | 324.6M |
| IPO Year | N/A | N/A |
| Metric | EFR | CAPR |
|---|---|---|
| Price | $11.21 | $26.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.14 |
| AVG Volume (30 Days) | 88.6K | ★ 5.7M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 9.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | N/A | ★ $11,130,509.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,736.03 |
| P/E Ratio | $7.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.95 | $4.30 |
| 52 Week High | $13.29 | $40.37 |
| Indicator | EFR | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 79.98 |
| Support Level | $11.07 | $4.30 |
| Resistance Level | $11.23 | $40.37 |
| Average True Range (ATR) | 0.10 | 2.60 |
| MACD | 0.02 | 2.56 |
| Stochastic Oscillator | 91.07 | 62.78 |
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.